This inventor holds 3 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Institut Pasteur De Lille, National Institute of Health and Medical Research. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 5,383 
3 out of 65 
3 out of 1,853 
Years Active: 2021-2025
Title: Philippe Gosset: Innovator in Monoclonal Antibody Research
Introduction
Philippe Gosset is a notable inventor based in Lille, France. He has made significant contributions to the field of medical research, particularly in the development of monoclonal antibodies for treating chronic obstructive pulmonary disease (COPD). With a total of 3 patents, his work addresses critical health challenges faced by patients suffering from this debilitating condition.
Latest Patents
Gosset's latest patents include innovative approaches to treating bacterial-induced exacerbations of COPD. One of his key inventions focuses on monoclonal antibodies specific for IL20-Rb, which are designed to enhance bacterial clearance and reduce inflammation in patients. This invention is crucial as acute exacerbations of COPD are often triggered by respiratory infections, leading to a decline in lung function and increased morbidity. Another patent relates to methods and pharmaceutical compositions for treating acute exacerbations of COPD through the antagonism of IL-20 cytokines, providing a promising avenue for therapeutic intervention.
Career Highlights
Throughout his career, Philippe Gosset has worked with prestigious institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Institut Pasteur de Lille. His research has significantly advanced the understanding of COPD and the potential for targeted therapies to improve patient outcomes.
Collaborations
Gosset has collaborated with esteemed colleagues, including Muriel Pichavant and Magdiel Perez-Cruz. These partnerships have fostered a collaborative environment that enhances the innovation and application of his research findings.
Conclusion
Philippe Gosset's contributions to the field of monoclonal antibody research are invaluable, particularly in the context of treating chronic obstructive pulmonary disease. His innovative patents and collaborations reflect a commitment to improving health outcomes for patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile